Chaozhou Three-Circle (Group) Co.,Ltd. (SHE:300408)

Ligand Pharmaceuticals Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	5,355	3,063	2,842	4,509	5,552	2,946
Trading Asset Securities	3,171	5,053	3,847	4,255	2,694	2,547
Cash & Short-Term Investments	8,526	8,116	6,688	8,764	8,246	5,493
Cash Growth	24.43%	21.35%	-23.69%	6.29%	50.12%	54.73%
Accounts Receivable	2,712	2,686	2,259	1,715	2,277	1,737
Other Receivables	21.76	28.66	44.23	83.75	151.25	167.31
Receivables	2,734	2,715	2,304	1,799	2,428	1,905
Inventory	2,171	2,181	1,754	1,886	1,797	885.47
Other Current Assets	582.94	590.09	533.95	371.75	315.9	79.96
Total Current Assets	14,014	13,602	11,279	12,821	12,787	8,363
Property, Plant & Equipment	6,286	6,352	5,812	5,918	5,047	3,166
Long-Term Investments	2.96	2,933	3,594	2.77	2.58	103.11
Goodwill	235.44	227.28	237.35	224.17	218.03	242.35
Other Intangible Assets	439.08	440.75	452.5	363.59	299	198.87
Long-Term Deferred Tax Assets	229.49	247.21	182.16	187.4	98.71	49.35
Long-Term Deferred Charges	15.38	17.64	19.08	24.68	19.65	14.63
Other Long-Term Assets	2,812	95.33	251.07	52.32	148.82	209.75
Total Assets	24,035	23,916	21,827	19,593	18,620	12,347
Accounts Payable	1,167	1,295	980.7	635.05	830.2	442.54
Accrued Expenses	152.94	384.52	324.42	343.33	317.23	199.65
Short-Term Debt	405.59	474.79	740.53	151.84	42.16	-
Current Portion of Leases	4.58	4.55	4.74	6.72	7.78	-
Current Income Taxes Payable	116.32	109.09	103.23	100.28	19.26	71.23
Current Unearned Revenue	41.07	30.78	22.61	18.62	25.36	35.71
Other Current Liabilities	302.47	295.21	224.3	227.43	332.01	20.73
Total Current Liabilities	2,190	2,594	2,401	1,483	1,574	769.86
Long-Term Debt	-	-	-	-	-	90
Long-Term Leases	21.98	22.25	26.57	30.64	1.74	-
Long-Term Unearned Revenue	1,039	1,061	879.65	732.22	609.43	539.31
Long-Term Deferred Tax Liabilities	362.93	365.7	278.57	242.93	213.35	104.88
Other Long-Term Liabilities	0.66	1.26	2.53	0.88	29.95	29.45
Total Liabilities	3,614	4,044	3,588	2,490	2,428	1,533
Common Stock	1,916	1,916	1,916	1,916	1,916	1,817
Additional Paid-In Capital	6,218	6,218	6,218	6,218	6,218	2,438
Retained Earnings	12,306	11,773	10,120	9,018	8,126	6,570
Comprehensive Income & Other	-26.4	-42.04	-21.09	-52.76	-70.71	-11.2
Total Common Equity	20,414	19,866	18,233	17,100	16,190	10,813
Minority Interest	5.93	5.69	5.9	3.74	1.28	0.18
Shareholders' Equity	20,420	19,872	18,239	17,103	16,192	10,814
Total Liabilities & Equity	24,035	23,916	21,827	19,593	18,620	12,347
Total Debt	432.15	501.59	771.85	189.21	51.69	90
Net Cash (Debt)	8,094	7,615	5,916	8,575	8,194	5,403
Net Cash Growth	36.21%	28.70%	-31.00%	4.65%	51.66%	56.16%
Net Cash Per Share	4.20	3.96	3.07	4.50	4.48	3.08
Filing Date Shares Outstanding	1,916	1,916	1,916	1,916	1,916	1,817
Total Common Shares Outstanding	1,916	1,916	1,916	1,916	1,916	1,817
Working Capital	11,824	11,008	8,879	11,337	11,213	7,593
Book Value Per Share	10.65	10.37	9.51	8.92	8.45	5.95
Tangible Book Value	19,740	19,198	17,543	16,512	15,673	10,372
Tangible Book Value Per Share	10.30	10.02	9.15	8.62	8.18	5.71
Buildings	-	2,736	2,322	2,027	1,397	1,206
Machinery	-	6,545	5,842	5,735	5,019	2,951
Construction In Progress	-	593.66	681.2	690.54	725.06	788.73

Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.